Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AVDL vs SUPN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVDL Captures Overall Composite Edge (62.9 BUY vs 54.3 HOLD), While SUPN Leads 5–1 on Growth & Valuation Pillars

AVDL Overall Winner 6-Pillar Tally: AVDL 1 – 5 SUPN Matrix Metrics: AVDL 6 – 4 SUPN

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Supernus Pharmaceuticals, Inc. (SUPN) on higher Unified Composite conviction (62.9/100 BUY vs. 54.3/100 HOLD) after splitting the core matrix 6–4 (led by Options & Positioning), while SUPN wins 5–1 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus SUPN at $28.61 (7.2x Forward P/E, 46.9% operating margin).

  • Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. SUPN 54.3/100 HOLD) and 0.14β · 2% Vol risk profile, whereas SUPN leads top-line expansion (+13.4% YoY revenue growth, 1.47x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile SUPN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVDL vs SUPN
AVDL NASDAQ Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50
SUPN NASDAQ
Supernus Pharmaceuticals, Inc.
Pharmaceutical Preparations
$28.61
+0.92% 1D
Market Cap $5.9B
TTM Revenue $1.37B
Forward P/E 7.2x
Beta / 30D Vol 0.64β · 120% Vol
Unified Composite Score
54.3 / 100 HOLD
Tech 63.0 Fund 64.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.9%), weak momentum, RSI 32
RSI-14: 31.6 · SMA20: $32.25 · SMA50: $38.16

6-Pillar Scorecard Institutional Category Breakdown (AVDL 1 – 5 SUPN)

Columns: Metric · AVDL · SUPN
1. Valuation Multiples SUPN
Forward P/E 28.8x 7.2x
Trailing P/E 16.8x 20.2x
PEG Ratio 0.07x 1.47x
EV / Revenue 8.5x 4.2x
2. Growth & Scale SUPN
Revenue Growth (YoY) +54.9% +13.4%
Earnings Growth (YoY) +0.0% +239.4%
TTM Revenue (USD) $249M $1.37B
Market Cap $2.1B $5.9B
3. Profitability & Quality SUPN
Gross Margin 94.9% 85.7%
Operating Margin 2.5% 46.9%
Net Profit Margin -0.1% 32.8%
Return on Equity (ROE) -0.3% -4.2%
4. Balance Sheet & Cash Flow SUPN
Cash Generation (TTM) $2.7M EBITDA $87M
Cash Flow Margin 1.1% EBITDA Mgn 6.3%
Net Cash / Leverage $1.01 Book/Sh · -0.3% ROE $140M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AVDL
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 2.4% (<1st %ile) 38.4% (6th %ile)
Put/Call OI Skew N/A 0.79x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat SUPN
OpEx & R&D Intensity N/A 38.8% of Rev ($533M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVDL (6) vs SUPN (4)
Institutional Metric AVDL SUPN Criterion Row Edge
Market Capitalization
Scale
$2.1B $5.9B Larger Scale SUPN
Trailing P/E Ratio
Valuation
16.8x 20.2x Lower Multiple AVDL
Forward P/E Ratio
Valuation
28.8x 7.2x Lower Multiple SUPN
Revenue Growth (YoY)
Growth
+54.9% +13.4% Higher Growth AVDL
Operating Margin (TTM)
Profitability
2.5% 46.9% Higher Margin SUPN
Net Profit Margin
Profitability
-0.1% 32.8% Higher Margin SUPN
Return on Equity (ROE)
Capital Efficiency
-0.3% -4.2% Higher ROE AVDL
52-Week Range Position
Momentum
89% ($6–$24) 8% ($26–$60) Stronger Trend AVDL
Beta / 30D Volatility
Risk Regime
0.14β · 2% Vol 0.64β · 120% Vol Lower Realized Risk AVDL
Unified Institutional Score
Composite Signal
62.9 / 100 (BUY) 54.3 / 100 (HOLD) Higher Composite AVDL
Trailing 12M Revenue (USD)
Operating Scale
$249M $1.37B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
94.9% 85.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.07x PEG · 8.5x EV/Rev 1.47x PEG · 4.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) $87M ($140M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVDL +0.69 pp
AVDL: +0.65% · SUPN: -0.04%
3M Horizon SUPN +20.01 pp
AVDL: -5.67% · SUPN: +14.34%
6M Horizon SUPN +20.01 pp
AVDL: -5.67% · SUPN: +14.34%
1Y Horizon SUPN +20.01 pp
AVDL: -5.67% · SUPN: +14.34%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs SUPN. Trailing 12-month operating profitability (AVDL 2.5% vs SUPN 46.9%) and valuation multiples (AVDL 28.8x vs SUPN 7.2x Forward P/E) are benchmarked directly in Pillar 4 below.

AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x
SUPN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.37B
Gross Margin85.7%
Op. Margin46.9%
ROE / Fwd P/E-4.2% · 7.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SUPN BREAKDOWN
95d in phase · OBV DISTRIBUTION
Current IV 38.4%
IV Percentile 6th %ile
Put/Call OI Skew 0.79x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SUPN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SUPN Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $5.9B market capitalization and 46.9% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($533M)
90D Engineering Disclosures 0 Published

Investor FAQ AVDL vs SUPN Key Questions & Quantitative Answers

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Supernus Pharmaceuticals, Inc. (SUPN) on higher Unified Composite conviction (62.9/100 BUY vs. 54.3/100 HOLD) after splitting the core matrix 6–4 (led by Options & Positioning), while SUPN wins 5–1 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus SUPN at $28.61 (7.2x Forward P/E, 46.9% operating margin). Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. SUPN 54.3/100 HOLD) and 0.14β · 2% Vol risk profile, whereas SUPN leads top-line expansion (+13.4% YoY revenue growth, 1.47x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile SUPN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SUPN leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with SUPN at +13.4% YoY revenue growth and +239.4% YoY earnings growth on $1.37B TTM revenue (85.7% gross margin, 46.9% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $1.37B for SUPN. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus 38.8% of Rev ($533M) (0 disclosures) for SUPN.

SUPN screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas SUPN trades at 7.2x Forward P/E, 20.2x Trailing P/E, 1.47x PEG, and 4.2x EV/Revenue (6.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus SUPN (-4.2% ROE) capital efficiency.

In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, SUPN carries 38.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.79x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.64β · 120% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.